FDA Oks Novartis's Zortress For Liver Transplantation - Quick Facts NASDAQ According to the company, Zortress is the first mammalian target of rapamycin (mTOR) inhibitor approved for use following liver transplantation. It is also ... In most EU member countries, Certican is also approved in kidney and heart transplantation ... |
